Lyell Immunopharma's total assets for Q3 2025 were $407.96M, an increase of 5.84% from the previous quarter. LYEL total liabilities were $78.84M for the fiscal quarter, a -8.88% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.